Therefore, we designed sequence-specific shRNAs to target the different nucleotide loci of LMP1 and performed a series of in vivo and in vitro experiments to investigate the therapeutic effect of sequence-specific shRNAs targeting LMP1 and its related molecular mechanisms in EBV-positive NPC. Here, PDLIM7 is linked to nasopharyngeal carcinoma.